PARP inhibitors that have been used clinically in the treatment of mCRPC are olaparib, rucaparib, niraparib, and talazoparib, and all of them can cause tumor cell death, but the mechanism of action varies between drugs. This evidence concerns the gene PARP1 and neoplasm.